Article Abstract

AURA 3: the last word on chemotherapy as a control arm in EGFR mutant NSCLC?

Authors: Terry L. Ng, D. Ross Camidge

Abstract

Although first and second generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have led to significant improvements in both objective response rate (ORR) and progression free survival (PFS) in advanced non-small cell lung cancer (NSCLC) patients with EGFR exon 19 deletion (exon 19 del) or p.Leu858Arg (L858R) point mutations, acquired resistance against EGFR TKIs develops after 9 to 13 months in most patients (1-4).

Refbacks

  • There are currently no refbacks.